(Q35787653)

10 August 2017

1 reference

title

Novel biological strategies in inflammatory bowel diseases (English)

1 reference

10 August 2017

2

Paul Rutgeerts

0 references

Séverine Vermeire

series ordinal

1

object named as

Severine Vermeire

1 reference

10 August 2017

publication date

1 February 2004

1 reference

Inflammatory Bowel Diseases

10 August 2017

published in

1 reference

10 August 2017

volume

10 Suppl 1

1 reference

10 August 2017

page(s)

S44-51

1 reference

Inflammatory Bowel Disease

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200402001-00010

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200402001-00010

Infliximab for the treatment of fistulas in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200402001-00010

Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200402001-00010

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200402001-00010

Predictors of response to infliximab in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200402001-00010

ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200402001-00010

Anti-tumour necrosis factor alpha (infliximab) in the treatment of severe ulcerative colitis: result of an open study on 13 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200402001-00010

Infliximab for refractory ulcerative colitis or indeterminate colitis: an open-label multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200402001-00010

Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200402001-00010

Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200402001-00010

Treatment of ulcerative colitis with an engineered human anti-TNFalpha antibody CDP571.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200402001-00010

Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200402001-00010

Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200402001-00010

Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200402001-00010

An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200402001-00010

An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200402001-00010

Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200402001-00010

Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200402001-00010

Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200402001-00010

Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200402001-00010

Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200402001-00010

Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200402001-00010

Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200402001-00010

Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200402001-00010

Treatment of Crohn's disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200402001-00010

Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200402001-00010

Treatment of murine colitis by Lactococcus lactis secreting interleukin-10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200402001-00010

Prevention of colitis by interleukin 10-transduced T lymphocytes in the SCID mice transfer model

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200402001-00010

Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200402001-00010

Interferon beta-1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200402001-00010

Antibody blockade of ICAM-1 and VCAM-1 ameliorates inflammation in the SAMP-1/Yit adoptive transfer model of Crohn's disease in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200402001-00010

A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200402001-00010

Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200402001-00010

Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200402001-00010

A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200402001-00010

Natalizumab for active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200402001-00010

Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200402001-00010

Response of refractory colitis to intravenous or oral tacrolimus (FK506).

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200402001-00010

Toxicity of mycophenolate mofetil in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200402001-00010

Mycophenolate mofetil in refractory inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200402001-00010

Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200402001-00010

NOD2/CARD15 does not influence response to infliximab in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200402001-00010

Response to infliximab treatment in Crohn's disease is not associated with mutations in the CARD15 (NOD2) gene: an analysis in 534 patients from two multicenter, prospective GCP-level trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200402001-00010

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200402001-00010

10.1097/00054725-200402001-00010

21 January 2018

Identifiers

DOI

1 reference

10 August 2017

1 reference